Sentinel Lymph Node Biopsy

Sentinel lymph node biopsy

Definition

Sentinel lymph node biopsy (SLNB) is a minimally invasive procedure in which a lymph node near the site of a cancerous tumor is first identified as a sentinel node and then removed for microscopic analysis. SLNB was developed by researchers in several different cancer centers following the discovery that the human lymphatic system can be mapped with radioactive dyes, and that the lymph node(s) closest to a tumor serve to filter and trap cancer cells. These nodes are known as sentinel nodes because they act like sentries to warn doctors that a patient's cancer is spreading.

The first descriptions of sentinel nodes come from studies of penile and testicular cancers done in the 1970s. A technique that uses blue dye to map the lymphatic system was developed in the 1980s and applied to the treatment of melanoma in 1989. The extension of sentinel lymph node biopsy to the treatment of breast cancer began at the John Wayne Cancer Institute in Santa Monica, California, in 1991. As of 2003, SLNB is used in the diagnosis and treatment of many other cancers, including cancers of the head and neck, anus, bladder, lung, and male breast.

Purpose

Sentinel lymph node biopsy has several purposes:

• Improving the accuracy of cancer staging. Cancer staging is a system that classifies malignant tumors according to the extent of their spread in the body. It is used to guide decisions about treatment.
• Catching the spread of cancer to nearby lymph nodes as early as possible.
• Defining homogeneous patient populations for clinical trials of new cancer treatments.

Description

A sentinel lymph node biopsy is done in two stages. In the first part of the procedure, which takes one to two hours, the patient goes to the nuclear medicine department of the hospital for an injection of a radioactive tracer known as technetium 99. A doctor who specializes in nuclear medicine first numbs the area around the tumor with a local anesthetic and then injects the radioactive technetium. He or she usually injects a blue dye as well. The doctor will then use a gamma camera to take pictures of the lymph nodes before surgery. This type of imaging study is called lymphoscintigraphy.

After the lymphoscintigraphy, the patient must wait several hours for the dye and the radioactive material to travel from the tissues around the tumor to the sentinel lymph node. He or she is then taken to the operating room and put under general anesthesia. Next, the surgeon injects more blue dye into the area around the tumor. The surgeon then uses a hand-held probe connected to a gamma ray counter to scan the area for the radioactive technetium. The sentinel lymph node can be pinpointed by the sound made by the gamma ray counter. The surgeon makes an incision about 0.5 in long to remove the sentinel node. The blue dye that has been injected helps to verify that the surgeon is removing the right node. The incision is then closed and the tissue is sent to the hospital laboratory for examination.

Preparation

Some cancer patients should not be given an SLNB. They include women with cancer in more than one part of the breast; women who have had previous breast surgery, including plastic surgery; women with breast cancer in advanced stages; and women who have had radiation therapy. Melanoma patients who have undergone wide excision (removal of surrounding skin as well as the tumor) of the original skin cancer are also not candidates for an SLNB.

Apart from evaluating the patient's fitness for an SLNB, no additional preparation is necessary.

Aftercare

A sentinel lymph node biopsy does not require extensive aftercare. In most cases, the patient goes home after the procedure or after an overnight stay in the hospital.

The surgeon will discuss the laboratory findings with the patient. If the sentinel node was found to contain cancer cells, the surgeon will usually recommend a full axillary lymph node dissection (ALND). This is a more invasive procedure in which a larger number of lymph nodes—usually 12–15—is surgically removed. A drainage tube is placed for two to three weeks and the patient must undergo physical therapy at home.

Risks

Risks associated with an SLNB include the following:

• Mild discomfort after the procedure.
• Lymphedema (swelling of the arm due to disruption of the lymphatic system after surgery).
• Damage to the nerves in the area of the biopsy.
• Temporary discoloration of the skin in the area of the dye injection.
• False negative laboratory report. A false negative means that there is cancer in other lymph nodes in spite of the absence of cancer in the sentinel node. False negatives usually result from either poor timing of the dye injection, the way in which the pathologist prepared the tissue for examination, or the existence of previously undiscovered sentinel nodes.

Normal results

Sentinel lymph node biopsies have a high degree of accuracy, with relatively few false negatives. A negative laboratory report means that there is a greater than 95% chance that the other nearby lymph nodes are also free of cancer.

Morbidity and mortality rates

Compared to axillary lymph node dissection, sentinel lymph node biopsy has a significantly lower rate of complications. One study found that only 2.6% of patients who had SLNB developed lymphedema, compared to 27% of patients who had ALND. Another study found that 71% of SLNB patients were able to return to normal activity within 4 days of the procedure, compared to 7% of the ALND patients.

Alternatives

Breast cancer patients who should not have a sentinel lymph node biopsy usually undergo an axillary lymph node dissection to determine whether their cancer has spread. Melanoma patients who have already had a wide excision of the original melanoma may have nearby lymph nodes removed to prevent the cancer from spreading. This procedure is called a prophylactic lymph node dissection.

Resources

periodicals

Burak, W. E., S. T. Hollenbeck, E. E. Zervos, et al. "Sentinel Lymph Node Biopsy Results in Less Postoperative Morbidity Compared with Axillary Lymph Node Dissection for Breast Cancer." American Journal of Surgery 183 (January 2002): 23-27.

Burrall, Barbara, and Vijay Khatri. "Still Debating Sentinel Lymph Node Biopsy?" Dermatology Online Journal 7 (2):1 [April 22, 2003].

Fukui, Y., T. Yamakawa, T. Taniki, et al. "Sentinel Lymph Node Biopsy in Patients with Papillary Thyroid Carcinoma." Cancer 92 (December 1, 2001): 2868-2874.

Golshan, M., W. J. Martin, and K. Dowlatshahi. "Sentinel Lymph Node Biopsy Lowers the Rate of Lymphedema When Compared with Standard Axillary Lymph Node Dissection." American Surgeon 69 (March 2003): 209-211.

McMasters, K. M., D. S. Reintgen, M. I. Ross et al. "Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement." Journal of Clinical Oncology 19 (June 1, 2001): 2851-2855.

Peley, C., E. Farkas, I. Sinkovics, et al. "Inguinal Sentinel Lymph Node Biopsy for Staging Anal Cancer." Scandinavian Journal of Surgery 91 (2002): 336-338.

Port, E. R., J. V. Fey, H. S. Cody III, and P. I. Borgen. "Sentinel Lymph Node Biopsy in Patients with Male Breast Carcinoma." Cancer 91 (January 15, 2001): 319-323.

Pow-Sang, Julio, MD. "The Spectrum of Genitourinary Malignancies." Cancer Control 9 (July-August 2002): 275-276.

Schmalbach, C. E., B. Nussenbaum, R. S. Rees, et al. "Reliability of Sentinel Lymph Node Mapping with Biopsy for Head and Neck Cutaneous Melanoma." Archives of Otolaryngology—Head and Neck Surgery 129 (January 2003): 61-65.

Tanis, Pieter J., Omgo E. Nieweg, Renato A. Valdés Olmos, et al. "History of Sentinel Node and Validation of the Technique." Breast Cancer Research 3 (2001): 109-112.

Uren, R. F., R. Howman-Giles, and J. F. Thompson. "Patterns of Lymphatic Drainage from the Skin in Patients with Melanoma." Journal of Nuclear Medicine 44 (April 2003): 570-582.

organizations

American Cancer Society (ACS). (800) ACS-2345. <www.cancer.org>.

National Cancer Institute (NCI). NCI Public Inquiries Office, Suite 3036A, 6116 Executive Boulevard, MSC8332, Bethesda, MD 20892-8322. (800) 4-CANCER or (800) 332-8615 (TTY). <www.nci.nih.gov>.

Society of Nuclear Medicine (SNM). 1850 Samuel Morse Drive, Reston, VA 20190. (703) 708-9000. <www.snm.org>.

Rebecca Frey, Ph.D.

WHO PERFORMS THE PROCEDURE AND WHERE IS IT PERFORMED?

---

An SLNB is usually performed in a hospital that has a department of nuclear medicine, although it is sometimes done as an outpatient procedure. The radioactive material or dye is injected by a physician who specializes in nuclear medicine. The sentinel lymph node is removed by a surgeon with experience in the technique. It is then analyzed in the hospital laboratory by a pathologist, who is a doctor with special training in studying the effects of disease on body organs and tissues.

The accuracy of a sentinel lymph node biopsy depends greatly on the skill of the surgeon who removes the node. Recent studies indicate that most doctors need to perform 20–30 SLNBs before they achieve an 85% success rate in identifying the sentinel node(s) and 5% or fewer false negatives. They can gain the necessary experience through special residency programs, fellowships, or training protocols. It is vital for patients to ask their surgeon how many SLNBs he or she has performed, as those who do these biopsies on a regular basis generally have a higher degree of accuracy.

QUESTIONS TO ASK THE DOCTOR

---

• Am I a candidate for sentinel lymph node biopsy?
• How many SLNBs have you performed?
• Do you perform this procedure on a regular basis?
• What is your false-negative rate?